STAT Plus: Follow the debate over Alkermes’ controversial new depression drug
APSTOCK
The FDA is convening a panel of experts to review a new drug to combat treatment-resistant depression. We're following the discussion live.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario